Clinical Trial Update: Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating the combination of tislelizumab and capecitabine for nasopharyngeal carcinoma with residual EBV DNA after radiotherapy, currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 2 | Status: RECRUITING